Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study

S Bianchi, Stefano Bianchi, Bianchi S, Busacca M, M Busacca, B Agnoli, Agnoli B, Massimo Candiani, M. Candiani, C. Calia, Calia C, M. Vignali, Vignali M
Human Reproduction · 1999 · vol. 14(5) , pp. 1335–1337 · doi:10.1093/humrep/14.5.1335 · PMID:10325289 · W2142407183
RCT OA: bronze CC0 ⤵ 74 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Three months of danazol therapy after laparoscopic surgery for stage III/IV endometriosis did not show a significant advantage over expectant management regarding fertility, pain recurrence, or disease recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of treatment with danazol was evaluated with respect to expectant management after laparoscopic conservative surgery. All patients conservatively operated at laparoscopy for stage III-IV endometriosis from July 1994 to October 1996 were requested to enter the study. Patients who underwent surgery for recurrent endometriosis were excluded from the study, as well as patients who had taken hormonal therapies before laparoscopy. Informed consent was obtained from 77 women who were randomized after surgery to treatment with danazol 600 mg daily for 3 months (n = 36) or to expectant management (n = 41). All patients were regularly followed up every 6 months for evaluation of fertility, recurrence of pain symptoms and disease. During the follow-up, six (55%) of the 11 infertile women allocated to danazol and eight (50%) of the 16 given no treatment became pregnant (not significant). Moderate/severe pelvic pain recurred during follow-up in seven (23%) of the 31 women with pelvic pain allocated to the danazol group and nine (31%) of the 29 allocated to no treatment; the respective cumulative pain recurrence rates at 12 months were 26 and 34% (log rank test, not significant). Three women (8.3%) treated with danazol and six (15%) who received no treatment had disease recurrence as demonstrated by gynaecological examination and/or pelvic ultrasonography (not significant). Our results do not demonstrate a significant advantage of 3 month danazol therapy after laparoscopic surgery for stage III-IV endometriosis with respect to postoperative expectant management.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Estrogen Antagonists Laparoscopy Laparoscopy Adult Adult Danazol Danazol Drug Administration Schedule Drug Administration Schedule Endometriosis Endometriosis Endometriosis Estrogen Antagonists Estrogen Antagonists Female Female Humans Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T20:58:57.924351+00:00
License: CC0 · commercial use OK